%0 Journal Article
%A Stoian, Raluca
%A Exner, Jan-Philipp Harald
%A Gainey, Mark
%A Erbes, Thalia
%A Gkika, Eleni
%A Popp, Ilinca
%A Spohn, Simon K B
%A Krug, David
%A Juhasz-Böss, Ingolf
%A Grosu, Anca-Ligia
%A Sprave, Tanja
%T Comparison of intraoperative radiotherapy as a boost vs. simultaneously integrated boosts after breast-conserving therapy for breast cancer.
%J Frontiers in oncology
%V 13
%@ 2234-943X
%C Lausanne
%I Frontiers Media
%M DKFZ-2023-01358
%P 1210879
%D 2023
%X Currently, there are no data from randomized trials on the use of intraoperative radiotherapy (IORT) as a tumor bed boost in women at high risk of local recurrence. The aim of this retrospective analysis was to compare the toxicity and oncological outcome of IORT or simultaneous integrated boost (SIB) with conventional external beam radiotherapy (WBI) after breast conserving surgery (BCS).Between 2009 and 2019, patients were treated with a single dose of 20 Gy IORT with 50 kV photons, followed by WBI 50 Gy in 25 or 40.05 in 15 fractions or WBI 50 Gy with SIB up to 58.80-61.60 Gy in 25-28 fractions. Toxicity was compared after propensity score matching. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method.A 1:1 propensity-score matching resulted in an IORT + WBI and SIB + WBI cohort of 60 patients, respectively. The median follow-up for IORT + WBI was 43.5 vs. 32 months in the SIB + WBI cohort. Most women had a pT1c tumor: IORT group 33 (55
%K SIB (Other)
%K adjuvant (Other)
%K breast cancer (Other)
%K intraoperative radiotherapy (IORT) (Other)
%K radiotherapy (Other)
%K toxicity (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37409247
%2 pmc:PMC10318399
%R 10.3389/fonc.2023.1210879
%U https://inrepo02.dkfz.de/record/277352